Encouraging activity of bicalutamide and everolimus in castration-resistant prostate cancer (CRPC): Early results from a phase I/II clinical trial

被引：0
|
作者：
Zhang, Hongyong
Wang, Yu
Ghosh, Paramita
Lara, Primo N., Jr.
Pasquinelli, Patricia
Beckett, Laurel
White, Ralph W. deVere
Pan, Chong-Xian
机构：
来源：
CANCER RESEARCH | 2010年 / 70卷
关键词：
D O I：
10.1158/1538-7445.AM10-3720
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3720
引用
收藏
页数：3
相关论文
共 50 条
  • [41] Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)
    Meulenbeld, Hielke J.
    de Bono, Johann S.
    Tagawa, Scott T.
    Whang, Young E.
    Li, Xiaoyun
    Heath, Karl H.
    Zandvliet, Anthe S.
    Ebbinghaus, Scot W.
    Hudes, Gary R.
    de Wit, Ronald
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013, 72 (04) : 909 - 916
  • [42] Results from a phase lb/II study of enzalutamide and metformin in men with castration resistant prostate cancer (CRPC).
    Parikh, Mamta
    Robles, Daniel
    Pan, Chong-xian
    Lara, Primo
    Yang, Joy C.
    Gao, Allen
    Evans, Christopher P.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [43] Phase 2 clinical trial of TORC1 inhibition with everolimus in men with metastatic castration-resistant prostate cancer
    George, Daniel J.
    Halabi, Susan
    Healy, Patrick
    Jonasch, Darius
    Anand, Monika
    Rasmussen, Julia
    Wood, Sarah Y.
    Spritzer, Charles
    Madden, John F.
    Armstrong, Andrew J.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2020, 38 (03) : 79.e15 - 79.e22
  • [44] An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
    Kabbinavar, Fairooz F.
    Zomorodian, Nazy
    Rettig, Matthew
    Khan, Faraz
    Greenwald, Daniel Reif
    Davidson, Sheldon J.
    DiCarlo, Brian Anthony
    Patel, Ravi
    Pandit, Lalita
    Chandraratna, Rosh
    Sanders, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [45] An open-label phase II clinical trial of the RXR agonist IRX4204 in taxane-resistant, castration-resistant metastatic prostate cancer (CRPC).
    Kabbinavar, Fairooz F.
    Zomorodian, Nazy
    Rettig, Matthew
    Khan, Faraz
    Greenwald, Daniel Reif
    DiCarlo, Brian
    Davidson, Sheldon J.
    Patel, Ravindranath
    Pandit, Lalita
    Chandraratna, Rosh
    Sanders, Martin
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (04)
  • [46] CLINICAL STUDY OF MDV3100 IN PROGRESSIVE CASTRATION-RESISTANT PROSTATE CANCER (CRPC)
    Scher, Howard I.
    Beer, Tomasz
    Higano, Celestia
    Efstathiou, Eleni
    Anand, Aseem
    Hirmand, Mohammad
    Hung, David
    Steve, Larson
    Fleisher, Martin
    Sawyers, Charles
    JOURNAL OF UROLOGY, 2009, 181 (04): : 230 - 230
  • [47] Phase Ib dose finding trial of intravenous panobinostat with docetaxel in patients with castration-resistant prostate cancer (CRPC)
    Rathkopf, D. E.
    Chi, K. N.
    Vaishampayan, U.
    Hotte, S.
    Vogelzang, N.
    Alumkal, J.
    Agrawal, M.
    Nydam, T. M.
    Fandi, A.
    Scher, H. I.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] A Phase II Study of GW786034 (Pazopanib) With or Without Bicalutamide in Patients With Castration-Resistant Prostate Cancer
    Sridhar, Srikala S.
    Joshua, Anthony M.
    Gregg, Richard
    Booth, Christopher M.
    Murray, Nevin
    Golubovic, Jovana
    Wang, Lisa
    Harris, Pamela
    Chi, Kim N.
    CLINICAL GENITOURINARY CANCER, 2015, 13 (02) : 124 - 129
  • [49] ANTITUMOUR ACTIVITY OF THE PARP INHIBITOR OLAPARIB IN UNSELECTED SPORADIC CASTRATION-RESISTANT PROSTATE CANCER (CRPC) IN THE TOPARP TRIAL
    Mateo, J.
    Hall, E.
    Sandhu, S.
    Omlin, A. G.
    Miranda, S.
    Carreira, S.
    Goodall, J.
    Gillman, A.
    Mossop, H.
    Ralph, C.
    Zafeiriou, Z.
    Lopez, R. Perez
    Tunariu, N.
    Ferraldeschi, R.
    Rodrigues, D. Nava
    Kunju, L. P.
    Robinson, D.
    Attard, G.
    Chinnaiyan, A.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2014, 25
  • [50] Docetaxel and curcuminoids (CCM) combination in patients with castration-resistant prostate cancer (CRPC): A phase II study.
    Mahammedi, Hakim
    Pouget, Melanie
    Planchat, Eloise
    Cure, Herve
    Durando, Xavier
    Bayet-Robert, Mathilde
    Van-Praagh, Isabelle
    Atger, Marc
    Guy, Laurent
    Abrial, Catherine
    Chollet, Philippe J. M.
    Eymard, Jean-Christophe
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
12345